Open AccessA case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
Author(s) -
Saito Naoto,
Hatanaka Takeshi,
Nakano Sachi,
Hazama Yoichi,
Yoshida Sachiko,
Hachisu Yoko,
Tanaka Yoshiki,
Yoshinaga Teruo,
Kashiwabara Kenji,
Kubo Norio,
Hosouchi Yasuo,
Tojima Hiroki,
Kakizaki Satoru,
Uraoka Toshio
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.6129
Subject(s) - medicine , bevacizumab , atezolizumab , lymph node , hepatocellular carcinoma , hepatectomy , oncology , surgery , resection , radiology , gastroenterology , cancer , chemotherapy , nivolumab , immunotherapy
Abstract An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients.